Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 3

VERTEX PHARMACEUTICALS INC / MA

Form 3 July 16, 2007

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, response...

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Kelly Lisa			2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]					
(Last)	(First)	(Middle)	07/12/2007	4. Relationship of Reporting Person(s) to Issuer			5. If Amendment, Date Origin Filed(Month/Day/Year)		
C/O VERTI PHARMAC INCORPOR WAVERLY	EEUTICAL RATED,Â 'STREET (Street) GE, MAA	130 02139		Director _X_ Officer (give title below	(Check all applicable) Director 10% Owner		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City)	(State)	(Zip)	Table I - Non-Derivative Securities Beneficially Owned						
1.Title of Secu (Instr. 4)	rity		2. Amount o Beneficially (Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nat Owne (Instr.	•		
Common St	ock		7,000 (1)		D	Â			
Common St	ock		360		I	401(k)		
Reminder: Repowned directly	_		ach class of securities benefic	ially SI	EC 1473 (7-02)			
·	Perso infor	ons who res	spond to the collection of ained in this form are not ond unless the form displ	t					

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

currently valid OMB control number.

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 3

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable a Expiration Date (Month/Day/Year) Date Exercisable Expiration Date		3. Title and A Securities Un Derivative Se (Instr. 4) Title	derlying	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option	10/31/2006(2) 0	07/30/2016	Common Stock	30,000	\$ 33.51	D	Â
Stock Option	04/23/2007(3) 0	01/23/2017	Common Stock	22,500	\$ 36.3	D	Â

Reporting Owners

Reporting Owner Name / Address		Relationships				
1	Director	10% Owner	Officer	Other		
Kelly Lisa C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET CAMBRIDGE, MA 02139	Â	Â	SVP, Human Resources	Â		

Signatures

Valerie L. Andrews, Attorney-In-Fact 07/16/2007

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Includes (i) 4,000 restricted shares granted on July 31, 2006, subject to a repurchase right that lapses in four equal annual installments and (1) (ii) 3,000 restricted shares vesting on January 24, 2011, subject to a repurchase right and to acceleration upon achievement of certain performance-based milestones.
- (2) Right to buy shares of Common Stock under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from July 31, 2006.
- (3) Right to buy shares of Common Stock under 2006 Stock and Option Plan, vesting in 16 equal quarterly installments from January 24, 2007.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2